{"@id":"https://bioecon.ru/technology/t-cell-engagers-against-solid-tumors/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://cn.bioecon.ru/technology/t-cell-engagers-against-solid-tumors/","json":"https://cn.bioecon.ru/api/v1/technology/t-cell-engagers-against-solid-tumors/index.json"},"id":"t-cell-engagers-against-solid-tumors","industries":["pharma","biomanufacturing"],"lang":"cn","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/agc-biologics/","https://bioecon.ru/companies/orf-genetics/","https://bioecon.ru/companies/wildtype/","https://bioecon.ru/companies/esco-aster/","https://bioecon.ru/companies/simple-planet/","https://bioecon.ru/companies/cellmeat/","https://bioecon.ru/companies/integriculture/","https://bioecon.ru/companies/lonza-group/","https://bioecon.ru/companies/shin-etsu-chemical/","https://bioecon.ru/companies/newlimit/","https://bioecon.ru/companies/cryoport-systems/"]},"maturity":7,"name":"针对实体瘤的T细胞衔接器双特异性抗体","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"双表位抗体分子工程设计"},{"n":2,"title":"Fc段沉默与长效循环设计"},{"n":3,"title":"致密间质渗透与浸润验证"},{"n":4,"title":"安全性与细胞因子释放综合征防控"}],"summary":"通过CD3将细胞毒性T淋巴细胞直接导向难治性实体瘤抗原的双特异性抗体架构，专为穿透致密间质并规避细胞因子释放综合征（CRS）而设计。","url":"/technology/t-cell-engagers-against-solid-tumors/","verified":"2026-11-22"}